Business Standard

Panacea Biotec, THSTI tie up to make broad Covid vax, trials in 15-18 mths

If things go according to plan this India-made vaccine could hit the market within the next two to three years

Panacea Biotec, THSTI tie up to make broad Covid vax, trials in 15-18 mths
Premium

Globally, work on developing vaccines that protect against beta-coronaviruses has begun, but most projects are still in pre-clinical stages

Sohini Das Mumbai
Panacea Biotec along with public sector institute Translational Health Science and Technology Institute (THSTI) have begun work on developing a coronavirus vaccine that would offer ‘broad protection’ against not only the Sars-CoV-2 virus, but also its cousins - Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The idea is to develop a pre-emptive vaccine for future coronavirus outbreaks.

If things go according to plan this India-made vaccine could be available to the public in the next two to three years.

Global vaccine body CEPI (the Coalition for Epidemic Preparedness Innovations) has already announced an award to develop

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 21 2022 | 5:14 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com